Oli Pharma Submits IPO Prospectus Highlighting Leadership in Oligonucleotide CRDMO Services

Aug 09, 2024 15:00 CST Updated 15:00

Olipharma

CDMO Service Provider

Meeting Review

01 The 13th Cytiva ISPADownstream Production Intensification Seminar

Olipharma Successfully Hosts the 13th Cytiva ISPA Symposium on Enhanced Oligonucleotide Downstream Production Technology

July 25, 2024, Cytiva ISPA (Oligo workshop) OligonucleotideDownstream Production Enhancement Technology SeminarHosted at the Suzhou Wuzhong District production base of Suzhou Olipharma Technology Co., Ltd.

This seminar specially invited Mr. Xu Haiwei, Technical Director of Suzhou Olipharma, to share the development status and market trends of the oligonucleotide industry in China and abroad, covering the development process, classification, the latest R&D status in China and abroad, and an analysis of future market prospects for small nucleic acid drugs.

During the event, Cytiva's senior downstream product experts engaged in in-depth discussions and exchanges with the on-site experts on topics ranging from the basic principles and common considerations of oligonucleotide synthesis processes to strategies for scaling up these processes, as well as the fundamental principles and scale-up strategies for purification/ultrafiltration processes.The atmosphere at the event was enthusiastic. Participants not only asked the lecturers various questions related to regulations, the industry, the market, equipment, applications, and more, but also got to know each other and engaged in active discussions during the exchanges, forming a positive industry interaction.Move。

Photos of the on-site event

02 The 3rd BIONNOVA Western Innovation Forum

July 30-31, 2024，The 3rd BIONNOVA Western Innovation Forum Successfully Concluded in Chengdu, Focusing on Antibody Drugs,This forum combines the breakthrough highlights of the biopharmaceutical industry throughout 2023, targets innovative breakthrough achievements in various fields, focuses on antibody drugs, cell and gene therapy, innovative and improved chemical drugs, nucleic acid drugs, mRNA vaccines, extends to peptide drugs and conjugated drugs such as ADC and PDC, and brings 15 exciting sub-forums covering R&D, clinical trials, CMC production processes, innovative cooperation, and investment project roadshows.

Olipharma was invited to participate, where it discussed the current status and development prospects of the small nucleic acid industry applications with fellow professionals from the biopharmaceutical industry on-site. They actively exchanged industry information and experiences, jointly promoting cooperative development in the nucleic acid industry.

Photos of On-site Activities

03 Small Nucleic Acids and ADC Drugs Symposium

August 1, 2024Successful Holding of the Small Nucleic Acid and ADC Drug Seminar. The conference was hosted byJointly organized by IPHASE/Hzey, HZTK, and Olipharma, and co-organized by the Chengdu High-Tech Zone Biotechnology Industry Association, aiming toFurther promote the rapid development of drug research and development in China, and facilitate upstream and downstream integration.。

Mr. Xu Haiwei, Technical Director of Suzhou Olipharma, was a specially invited guest at this seminar, combiningWith over a decade of extensive experience and practical insights from Olipharma, this article succinctly outlines the key considerations in the process research and impurity control of oligonucleotide drugs, providing reference and inspiration for industry peers.

This SeminarTargeting frontline technical personnel from innovative pharmaceutical companies, CROs, research institutes, testing organizations, etc., through online platforms from Olipharma,IPHASE, Biocytogen,DXY,Introduction of Resolian Bioanalysis by Multiple Experts Online, explored the difficulties and issues in various drug development experiments, providing more solutions and strategies for the smooth progress of drug development, and received unanimous praise.

About Olipharma

Suzhou Olipharma Technology Co., Ltd. is a professional medicinal nucleic acid CRDMO.Suzhou Olipharma Technology Co., Ltd. provides customers with "one-stop" services including nucleic acid drug discovery, laboratory R&D, process and analytical development, CMC services, API production, and drug registration. The technical team of Olipharma comes from one of the earliest groups in China to engage in the development of nucleic acid drug production processes and CMC research, possessing extensive experience in project development and product registration. Currently, the company has established four core technology platforms leading in the industry: nucleic acid solid-phase synthesis, chemical modification and conjugation, process development and analysis, as well as CMC pharmaceutical research. It has also launched in-depth collaborations with multiple pharmaceutical companies and biotechnology firms both domestically and internationally.

In 2023, the company's 3,000㎡ pilot platform compliant with GMP standards officially began offering services, focusing on helping clients address critical challenges such as small nucleic acid drug process scale-up and CMC pharmaceutical research. The company will continue to provide compliant, high-quality, reliable, and efficient services to enhance clients' R&D efficiency, accelerate product registration and market entry, and jointly support the entire process of small nucleic acid drugs from preclinical to commercial production.

Contact Us

Email: order@olipharma.com

Official Website: www.olipharma.com

R&D Center: No. 168, Yuanfeng Road, Yushan Town, Kunshan City, Jiangsu Province

Production Base: Building C3, Phase I Factory, No. 999 Yishanhu Road, Guoxiang, Wuzhong District, Suzhou City, Jiangsu Province

Common Technology Platform: 202, 2nd Floor, No. 2 Yard, No. 21 Baoshen South Street, Beijing Daxing District Biomedical Industry Base